The purpose of the study is to determine the dose limiting toxicities and maximum tolerated
dose of motexafin gadolinium when administered with docetaxel and cisplatin in patients with
Non-small Cell Lung Cancer.
A cycle consists of 3 weeks. During week 1, patients receive MGd, docetaxel, and cisplatin
treatment followed by 2 weeks without treatment.
Eligible patients will receive 1 or 2 doses of MGd, depending on cohort, and a single dose
of docetaxel and cisplatin at 75 mg/m² during the first week of each cycle. Additionally,
tumor response will be evaluated at the end of even numbered cycles (2, 4, and 6). Patients
may stay on the study a maximum of 6 cycles.
- ≥ 18 years old
- ECOG score of 0, 1, or 2
- Histologically confirmed diagnosis of non-small cell lung cancer
Laboratory values demonstrating inadequate function of the following:
- Bone marrow
- Peripheral neuropathy Grade 2 or higher
- Greater than 2 prior chemotherapy regimens